XML 123 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
ACQUISITION-RELATED CHARGES AND PRODUCT DISCONTINUATION, NET - Product Discontinuance (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Restructuring Reserve [Roll Forward]      
Severance-related expenses $ 26,371 $ 0 $ 494
Total acquisition-related charges 40,900 4,899 150
Changes in contingent consideration (after an acquisition) 989 (5,204) (16,672)
Department of Justice settlement 0 0 3,500
Total acquisition-related charges, product discontinuation and other 42,911 5,166 25,230
DepoCyte      
Restructuring Reserve [Roll Forward]      
Discontinuation of DepoCyt(e) 0 (188) 159
Nuance Biotech Co. Ltd.      
Restructuring Reserve [Roll Forward]      
Discontinuation of DepoCyt(e) 3,000 0 0
Flexion      
Restructuring Reserve [Roll Forward]      
Changes in contingent consideration (after an acquisition) (1,174) 0 0
Myoscience Acquisition      
Restructuring Reserve [Roll Forward]      
Acquisition related fees 700 200 4,900
Changes in contingent consideration (after an acquisition) (2,163) 5,204 16,672
Acquisition-related fees      
Restructuring Reserve [Roll Forward]      
Acquisition related fees 10,963 0 4,211
Other acquisition expenses      
Restructuring Reserve [Roll Forward]      
Acquisition related fees $ 3,566 $ 150 $ 194